Milestones

2024

Awarded the title of 'National H₹‌₽£igh-tech Enterprise' for 17 consecutiveΩ✘ years Awarded the t✘≤☆&itle of 'Top 20 Chinese Pharmac✔∞eutical R&D Companieπ€↓πs' for 8 consecutive years Submitted r≈←₩egistration applications for 10 f≤ ε£ormulation products in China, obtaφ∞ining over 80 various registrat₩₽∑ion approvals Obtained re↓↑∏gistration numbers for 10 a‍₩λctive pharmaceutical in↓←gredients from FDA, CDE, Taiw≥​≈an Ministry of Health and ₹$¶↑Welfare, and other institutions Submi>&tted 12 new patent applications,₽☆© with a total of over 60 invenεΩ<tion patents Achieve∏®d a cumulative factory techn$'÷ology transfer of over 130 "¶items to client companies

2023

Awarded the title of 'National Hig"≈♦βh-tech Enterprise' for 16 ‍λ£consecutive years Awarded the title∞' of 'Top 20 Pharmaceutical R&D Com↕ ×'panies in China' for 7 c☆∞onsecutive years Has obtai∞↔♦∞ned more than 70 clinicalφ¥↑, production licenses, and neΩ$w drug certificates approved by th‌$<φe National Medical Prod₩± ucts Administration of Chin×♦≈→a Has submitted more t↔☆ε↕han 10 international regi® stration applications to ×÷the FDA, EU, etc. Cumulativel★γ•♠y achieved over a hundred technology trβ¶​¶ansfers to client compan•€"Ωies Completed multiple technology ach€€ievements transformatio♣ &n and industrialized ∏✘$♠production of over 30 series products

2022

More than 20 new invention pateβπnt applications Two raw materia​ ≈↔l drug varieties registered with≥"λ CDE transferred to A F¥×™ive formulation varieti≤λ♥es obtained production licenses Shangh♣™​♠ai branch established to<→ strengthen business expan"‌€sion and layout

2021

Obtain the first CEP certificateObtain CNAS certification certificδ≠&ate First submission o÷♥≈f MAH certification and obtain B cer♠≈♠tificate Two raw material drug varieλ‌®ties CDE transfer to A

2020

The R&D office building≈× of Jinghai Industrial Park i£>®"s officially in use. Establish a strategic partnership with± ×Ω Zezheng Pharmaceutical.

2019

The subsidiary Haimei Ocean was estα××↔ablished, and international business ↕∞ operates independently. Submitted registration applications to ♥♣∏the EU and FDA Ranked among the top 20 ↔≥©pharmaceutical R&D companies in Chε≤&ina for consecutive years Pilot u→•♠nit for integration of inform×ε↕atization and industrialization Woλ↔n the T100 New Technology and£∞ New Product Innovation A÷φction Enterprise Award

2018

Establish a strategic partner¶ ship with PPC Jiaseng Consecutivel$↔y ranked among the top 20 pharmaceutic®★→al R&D companies in China

2017

Establish a strategic part& ​nership with Boteng Pharmaceutical Awλ♦"♣arded the title of one of the t≈÷∞φop 20 pharmaceuticalβ↑‌¶ R&D companies in China

2016

The subsidiary Haimeiyuan w®™as established, and the CRO bus≥φ♠iness operates independently.

2015

The subsidiary Haimeitong was δ≤ established, and the raw mate§δrials and intermediates busin•÷®ess operates independentl↑π♥<y. Establish an employee sto✘σσck ownership platform and complet≈±αe the shareholding system transformati>' on.

2013

Obtain the first patent™< certificate

2012

Obtained the first new drug certificat↓&‍↕e Obtained the Beijing☆♥ § municipal enterprise techαΩγ↑nology research and develo∑↑₽<pment institution cer₽←tificate First accepted foreign cust±‌‍♥omer audit

2011

Investing in Shandong Kongfu Phaσ≥rmaceutical

2008

Establish a strategic partnershi✘"p with Beihua Hengye

2007

Awarded the title of National₩₩ High-tech Enterprise

2006

Establish a new drug resear ♦ch and development cente≠±®r

2005

Established Haibu Pharmaceutical